News
EVAX
4.125
-0.12%
-0.005
Weekly Report: what happened at EVAX last week (0415-0419)?
Weekly Report · 3d ago
Evaxion Biotech Advances Personalized Cancer Vaccine
TipRanks · 04/17 14:27
BRIEF-Evaxion Announces Phase 2 Clinical Trial Update
Evaxion Biotech A/S announces Phase 2 Clinical Trial Update. First patient completed DOSING with personalized cancer vaccine. The trial is on track for a one-year clinical readout in Q3 2024, the company says. Evaxion is developing a cancer vaccine called EVX-01.
Reuters · 04/17 12:19
EVAXION BIOTECH A/S - FAVORABLE SAFETY PROFILE CONFIRMED
Reuters · 04/17 12:00
Weekly Report: what happened at EVAX last week (0408-0412)?
Weekly Report · 04/15 12:22
Weekly Report: what happened at EVAX last week (0401-0405)?
Weekly Report · 04/08 12:27
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 04/03 10:40
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
TipRanks · 04/03 10:31
Health Care Sector Update for 04/02/2024: HUM, UNH, EVAX, OCGN
NASDAQ · 04/02 17:55
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. MSP Recovery (NASdaq:LIFW) shares moved upwards by 33.26%. Q4 earnings report came out 4 days ago. Losers Acorda Therapeutics and Gritstone Bio.
Benzinga · 04/02 16:31
Evaxion Biotech Raised to Buy From Neutral by Ladenburg Thalmann
Dow Jones · 04/02 15:49
Evaxion Biotech Price Target Announced at $8.00/Share by Ladenburg Thalmann
Dow Jones · 04/02 15:49
Ladenburg Thalmann Upgrades Evaxion Biotech to Buy, Announces $8 Price Target
Benzinga · 04/02 15:39
Evaxion’s Promising Vaccine Candidate Battles Superbug
TipRanks · 04/02 12:27
EVAXION AND UNDISCLOSED COLLABORATOR ANNOUNCE ENCOURAGING RESULTS FOR EVX-B1 VACCINE ANTIGENS AGAINST STAPHYLOCOCCUS AUREUS INFECTION
Reuters · 04/02 11:00
Weekly Report: what happened at EVAX last week (0325-0329)?
Weekly Report · 04/01 12:23
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Evaxion aims to use artificial intelligence to design vaccines for cancer immunotherapy and infectious diseases. The company has already established three collaborations and has raised enough cash to last through 2024. Evaxion's AI models show promise in identifying protective antigens and designing personalized cancer vaccines. Big pharma interest, proof-of-concept preclinical and clinical data are compelling reasons to be bullish on EVAX. However, the company needs to raise more cash to progress its pipeline.
Seeking Alpha · 03/31 10:39
Evaxion Biotech Announces Upcoming Annual Meeting
TipRanks · 03/29 13:57
EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023
Evaxion Biotech reported earnings per share of -$1.60. The company reported revenue of $73,000. This met the analyst estimate for EPS of $1.50. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 03/27 17:52
Evaxion Biotech ADS GAAP EPS of -$0.81
Seeking Alpha · 03/27 17:49
More
Webull provides a variety of real-time EVAX stock news. You can receive the latest news about Evaxion Biotech A/S through multiple platforms. This information may help you make smarter investment decisions.
About EVAX
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.